Business Wire - October 19, 2001

"We are very pleased to have been selected as a primary pharmacy provider for this important study," said Steve Westlund, Kaire's Chief Executive Officer. "This is a milestone event for us, with significant revenue implications. We anticipate the DAART study will increase our patient base by 25% to 40% over a period of six months from the date the DAART study begins, which is in approximately two weeks. The focus of our rapidly growing Health Advocate Program is medication compliance. The study is also important from the standpoint of creditability. We believe this can lead to other high profile alliances within that sector of the medical community engaged in the fight against HIV. Additionally, we are beginning the next phase of the program that involves recruitment of Health Advocates from across the country. We believe the foundation we have built in southern California can be successfully duplicated in virtually every region of the country."

The patients in the Health Advocate Program require an average of twelve hundred dollars per month in billable prescription medications. The Company's gross profit margins range from 8% for ADAP, to 16% for medical. Currently, approximately 65% of its patients are enrolled in ADAP with the balance in medical. Kaire anticipates the patients from the DAART study will follow that ratio.

Specific Aims and Purpose of the Study:

The study is a four-year collaborative project to evaluate the efficacy and feasibility of three models of adherence support for Highly Active Antiretroviral Therapy (HAART) within a large urban public health system of care. Three adherence models will be evaluated in this project: 1) a standard care (SOC) model that includes individual counseling by the primary provider and pharmacist; 2) an intensive adherence support program (IAP) model in which the HIV-infected person has at least once-weekly contact with adherence support staff; and 3) a directly administered antiretroviral therapy (DAART) model in which HAART medications are dispensed by dose and a per-dose medication record is maintained.

The major aims of the study are to compare the following among the three arms of care:

-- 1) To compare virologic and immunologic responses to therapy.

-- 2) To compare the incidence of opportunistic diseases and death.

-- 3) To compare the development of antiretroviral resistance.

-- 4) To compare the levels of adherence to antiretroviral therapy.

-- 5) To compare the cost and feasibility of the implementation of each of the three adherence models.

-- 6) To compare health care utilization costs.

-- 7) To evaluate pharmacokinetic correlates of outcome.

Data from this study will be used to guide recommendations regarding the utility and feasibility of an intensive adherence support program and a directly administered antiretroviral therapy (DAART) model for improving adherence to HAART.

About Kaire, Inc.

KAIRE provides specialized pharmacy care to bed and board facilities through its Classic Care Pharmacy, and HIV patients through its YesRx Health Advocate program. Kaire joint venture partner Stason Biotech is engaged in the research and development of compounds and testing measures for the treatment of pathogenic viral infections as well as other clinical applications related to solid prescription drug formations. Stason Biotech also provides quantitative laboratory analysis to research facilities engaged in regional blood flow studies under laboratory conditions.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "ACT"). In particular, when used in the preceding discussion, the words "estimated," "believe," "optimistic," "expect" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the ACT and are subject to risks and uncertainties, and actual results could differ materially from those expressed in any forward-looking statements. Such risks and uncertainties include, but are not limited to, unfavorable market conditions, increased competition, limited working capital, failure to implement business strategies, and other risks. For other company information, visit the corporate Web site at www.kaireholdingsinc.com.

CONTACT: CEOcast Inc., New York Mathew Henderson, 212/732-4300 www.KaireHoldingsInc.com www.CEOcast.com

011019
BW011008

Copyright © 2001 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .